Physician profile
Robert S Weiner
NPI 1518982776
$42,812.43
in general payments reported to CMS, 2019-2025
31 companies · $2,571 in 2025
The $2,571 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,418 · 2020: $1,116 · 2021: $1,502 · 2022: $26K · 2023: $1,661 · 2024: $957 · 2025: $2,571.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,067 · Honoraria: $2,048 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,000 · Education: $73.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,066.74 |
| Honoraria | $2,047.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,000.00 |
| Education | $73.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $24,729.53 | 2019-2024 | Xarelto |
| Amgen INC. | $8,674.56 | 2019-2020 | |
| Pharmaessentia USA Corporation | $2,260.76 | 2023-2025 | Besremi |
| Novartis Pharmaceuticals Corporation | $1,632.80 | 2021-2025 | |
| Janssen Biotech, INC. | $1,536.03 | 2019-2025 | Tecvayli, Darzalex, Rybrevant |
| Daiichi Sankyo INC. | $648.19 | 2019-2024 | Vanflyta, Injectafer |
| Genzyme Corporation | $525.79 | 2020-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $487.54 | 2019-2025 | Iclusig |
| Seagen INC. | $369.73 | 2021-2023 | Padcev |
| E.R. Squibb & Sons, L.L.C. | $296.13 | 2020-2024 | Eliquis |
| Celgene Corporation | $239.43 | 2021-2025 | Reblozyl |
| Incyte Corporation | $224.00 | 2022-2023 | Monjuvi |
| Alexion Pharmaceuticals, INC. | $207.89 | 2019-2024 | Ultomiris |
| Mirati Therapeutics, INC. | $158.32 | 2023-2024 | Krazati |
| Genentech USA, INC. | $145.40 | 2019-2023 | Columvi, Polivy |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Puma Biotechnology, INC. | $119.67 | 2019 | |
| Blueprint Medicines Corporation | $113.96 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $99.24 | 2020-2025 | |
| Kyowa Kirin, INC. | $75.80 | 2021-2022 | |
| Pfizer INC. | $37.61 | 2021-2025 | |
| Beone Medicines USA, INC. | $30.43 | 2025 | Brukinsa |
| Acrotech Biopharma INC. | $29.86 | 2025 | Beleodaq |
| Geron Corporation | $25.48 | 2025 | Rytelo |
| Cti Biopharma Corp. | $24.30 | 2023 | Vonjo |
| Deciphera Pharmaceuticals INC. | $22.49 | 2024 | Qinlock |
| Shield Therapeutics INC | $21.71 | 2024 | |
| Beigene USA, INC. | $19.83 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $15.75 | 2021 | |
| Syndax Pharmaceuticals, INC. | $15.02 | 2025 | Revuforj |
| Rigel Pharmaceuticals, INC. | $13.26 | 2022 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Weiner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.